Physician profile
James Abraham
NPI 1427276732
$3,569.10
in general payments reported to CMS, 2019-2025
15 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.15 · 2023: $517 · 2024: $636 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Education: $1,500 · Travel and Lodging: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.95 |
| Education | $1,500.00 |
| Travel and Lodging | $255.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,771.99 | 2025 | |
| Inspire Medical Systems, INC. | $550.50 | 2023-2025 | Inspire |
| Abbvie INC. | $214.95 | 2023-2025 | Viberzi, Linzess, Skyrizi |
| Celgene Corporation | $212.97 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $147.77 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $128.25 | 2023-2024 | Stelara |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $119.03 | 2023 | Zeposia |
| Astrazeneca Pharmaceuticals Lp | $117.94 | 2025 | Fasenra |
| Pfizer INC. | $75.31 | 2024 | |
| Boston Scientific Corporation | $40.15 | 2022 | |
| Biocon Biologics INC | $22.00 | 2023 | Hulio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.62 | 2023 | Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.33 | 2024 | Entyvio |
| Phathom Pharmaceuticals, INC. | $3.30 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.